All In Biotech

Drug Trial Radar · NCT04541186

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

86

Actual

Start

Sep 1, 2020

Primary completion

May 19, 2022

Study completion May 31, 2022

Sponsor

Lead sponsor
89bio, Inc.Industry
Sponsor type
Industry
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly \[QW\] or every 2 weeks \[Q2W\]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • PegozaferminDrug

    Subcutaneous injection

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)Time frame: Baseline, Week 8

Locations

48 sites in 4 countries. Site status is shown where the registry gives one.

  • 89Bio Clinical Study Site

    La Mesa, California

  • 89Bio Clinical Study Site

    San Francisco, California

  • 89Bio Clinical Study Site

    Clearwater, Florida

  • 89Bio Clinical Study Site

    Greenacres City, Florida

  • 89Bio Clinical Study Site

    Jacksonville, Florida

  • 89Bio Clinical Study Site

    Miami, Florida

  • 89Bio Clinical Study Site

    Miami, Florida

  • 89Bio Clinical Study Site

    Miami Lakes, Florida

  • 89Bio Clinical Study Site

    Miami Lakes, Florida

  • 89Bio Clinical Study Site

    North Miami Beach, Florida

  • 89Bio Clinical Study Site

    Orlando, Florida

  • 89Bio Clinical Study Site

    Tampa, Florida

  • 89Bio Clinical Study Site

    Lawrenceville, Georgia

  • 89Bio Clinical Study Site

    Quincy, Illinois

  • 89Bio Clinical Study Site

    Wauconda, Illinois

  • 89Bio Clinical Study Site

    West Des Moines, Iowa

  • 89Bio Clinical Study Site

    Louisville, Kentucky

  • 89Bio Clinical Study Site

    Olive Branch, Mississippi

  • 89Bio Clinical Study Site

    Albany, New York

  • 89Bio Clinical Study Site

    Greensboro, North Carolina

  • 89Bio Clinical Study Site

    Morganton, North Carolina

  • 89Bio Clinical Study Site

    Marion, Ohio

  • 89Bio Clinical Study Site

    Summerville, South Carolina

  • 89Bio Clinical Study Site

    Chattanooga, Tennessee

  • 89Bio Clinical Study Site

    Kingsport, Tennessee

  • 89Bio Clinical Study Site

    Austin, Texas

  • 89Bio Clinical Study Site

    Dallas, Texas

  • 89Bio Clinical Study Site

    Dallas, Texas

  • 89Bio Clinical Study Site

    Houston, Texas

  • 89Bio Clinical Study Site

    Lampasas, Texas

  • 89Bio Clinical Study Site

    Magnolia, Texas

  • 89Bio Clinical Study Site

    Manassas, Virginia

  • 89Bio Clinical Study Site

    Pardubice, Czechia

  • 89Bio Clinical Study Site

    Prague, Czechia

  • 89Bio Clinical Study Site

    Prague, Czechia

  • 89Bio Clinical Study Site

    Prague, Czechia

  • 89Bio Clinical Study Site

    Prague, Czechia

  • 89Bio Clinical Study Site

    Baja, Hungary

  • 89Bio Clinical Study Site

    Békéscsaba, Hungary

  • 89Bio Clinical Study Site

    Budapest, Hungary

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.